Home > Boards > US Listed > Biotechs > Gamida Cell Ltd. (GMDA)

Gamida Cell price target raised to $25 from

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 120
Posts 25,368
Boards Moderated 8
Alias Born 02/07/04
160x600 placeholder
Gamida Cell to Present at the 20th Annual Needham Virtual Healthcare Conference Business Wire - 4/7/2021 8:00:00 AM
Gamida Cell Presents Efficacy & Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at th... Business Wire - 3/15/2021 10:24:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 3/11/2021 4:36:22 PM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 3/11/2021 4:02:23 PM
Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) Edgar (US Regulatory) - 3/11/2021 3:34:31 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 3/11/2021 6:04:18 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 3/9/2021 4:09:39 PM
Gamida clibs 5.6% despite a Q4 miss, provides 2021 guidance Seeking Alpha - 3/9/2021 11:22:41 AM
Gamida Cell EPS misses by $0.35; outlook Seeking Alpha - 3/9/2021 7:05:01 AM
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update Business Wire - 3/9/2021 7:00:00 AM
Gamida Cell to Present at Upcoming Investor Conferences Business Wire - 3/3/2021 7:00:00 AM
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast Business Wire - 3/2/2021 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-3) Edgar (US Regulatory) - 3/1/2021 4:40:43 PM
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Soc... Business Wire - 3/1/2021 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/26/2021 3:13:08 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/17/2021 3:11:52 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/16/2021 2:22:05 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/16/2021 8:58:20 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/16/2021 8:30:16 AM
Gamida Cell launches $75M financing with Highbridge Capital Management Seeking Alpha - 2/16/2021 8:04:19 AM
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management Business Wire - 2/16/2021 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 5:53:48 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/12/2021 4:46:15 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 2/12/2021 3:13:10 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 2/10/2021 4:02:17 PM
midastouch017   Wednesday, 02/10/21 11:39:40 AM
Re: CYDYWinning post# 255
Post # of 299 
Gamida Cell price target raised to $25 from $13 at
Piper Sandler Piper Sandler analyst Edward Tenthoff
raised the firm's price target on Gamida Cell to $25
from $13 and keeps an Overweight rating on the shares.
The analyst is citing the company's Phase 3 omidubicel
data presented at the TCT Annual Meeting that showed
"significantly lowered rate of serious infection" and
reduced hospital stay.
Tenthoff adds that along with
less stringent HLA matching requirements, omidubicel
can dramatically expand access and improve outcomes
for HSCT patients, further stating that he is
increasing his modeled value on omidubicel to
$793M from $550M

https://thefly.com/landingPageNews.php?id=3244394&headline=GMDA-Gamida-Cell-price-target-raised-to--from--at-Piper-Sandler

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences